The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Phase I
PBTC-042: Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors. Pediatric Brain Tumor Consortium; Gururangan, Sridharan. (919) 668-6288
Phase I/II
ADVL1312: A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors. COG Phase 1 Consortium; Cole, Kristina Ann. (267) 426-2285
ADVL1411: A Phase 1/2 Study of BMN 673 (IND# 121510), an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies. COG Phase 1 Consortium; Schafer, Eric Stephen. (832) 825-4241
URCC-13070: Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers. University of Rochester; Mohile, Supriya Gupta. (585) 275-9319
Phase II
9416: A Randomized Phase II Trial of Cisplatin with or Without Wee1 Kinase Inhibitor MK-1775 for First-Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN). University Health Network-Princess Margaret Hospital; Winquist, Eric William. 519-685-6840
Phase III
E2112: A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer. ECOG-ACRIN Cancer Research Group; Connolly, Roisin M. (410) 614-9217
Other Phases
AALL14B4-Q: IRF-4, a Novel Tumor Suppressor in Pediatric BCR-ABL+ B-ALL. Children’s Oncology Group; Abrams, Scott. (716) 845-4375
AAML14B2-Q: Functional Proteomics for Stratification and Therapeutic Targeting of Chemotherapy Resistance in Acute Myeloid Leukemia. Children’s Oncology Group; Kentsis, Alex. (646) 888-2593
AAML14B3-Q: Targeting the STAT Pathway in Leukemia Stem Cells in Acute Myelogenous Leukemia. Children’s Oncology Group; Stevens, Alexandra Mclean. (832) 824-4824
ABTR13B1-Q: B-Lapachone as a Novel Targeted Therapy for Pediatric Cancers. Children’s Oncology Group; Laetsch, Theodore Willis. (214) 648-3896
Pilot Phase
ABTC-1302: Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma. Adult Brain Tumor Consortium; Cloughesy, Timothy Francis. (310) 825-5321
